Search results
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbuster
Quartz· 6 days agoPharma giant Pfizer said that its lung cancer drug Lorbrena could reach blockbuster status by 2030...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Morningstar· 3 days agoPfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive ...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
FOX Business· 6 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Pfizer's LORBRENA shows sustained NSCLC patient benefit over five years By Investing.com
Investing.com· 6 days agoPfizer Inc. (NYSE: NYSE:PFE) has released new data from its Phase 3 CROWN trial, which shows a...
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer...
Benzinga· 6 days agoOn Friday, Pfizer Inc PFE released longer-term follow-up results from the Phase 3 CROWN trial...
... Navigation, Expands Its Leadership Team for Strategic Growth with Product and Business ...
Healthcare Dive· 18 hours agoAda Health Inc. (‘Ada Health’), along with its parent company, Ada Health GmbH, today announced the expansion of its leadership team with Nick Altebrando joining as Chief ...
Moderna Wins Second-Ever Approval. But It Could Dominate Pfizer, GSK.
Investor's Business Daily· 6 days agoLike rivals Pfizer (PFE) and GSK (GSK) — which gained their approvals and launched last year —...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 7 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Chutes & Ladders—Roche veteran James Sabry hangs up his hat
FierceBiotech· 7 days agoPlease send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here...
ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy
FierceBiotech· 1 day ago“I think that people finally are showing up like in the old days,” Eliav Barr, M.D., Merck & Co.’s...